WORLD INTELLECTUAL PROPERTY ORGANIZATION



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (51) International Patent Classification 6: WO 97/29774 (11) International Publication Number: A61K 45/06 **A1** (43) International Publication Date: 21 August 1997 (21.08.97) (74) Agents: BULOCK, Joseph, W. et al.; G.D. Searle & Co., PCT/US97/01421 (21) International Application Number: Corporate Patent Dept., P.O. Box 5110, Chicago, IL 60680-5110 (US). (22) International Filing Date: 11 February 1997 (11.02.97) (30) Priority Data: (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, 08/600,655 13 February 1996 (13.02.96) US BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, (60) Parent Application or Grant PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, (63) Related by Continuation UG, US, UZ, VN, YU, ARIPO patent (KE, LS, MW, SD, US 08/600,655 (CON) SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, Filed on 13 February 1996 (13.02.96) TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, (71) Applicant (for all designated States except US): G.D. SEARLE TG). & CO. [US/US]; Corporate Patent Dept., P.O. Box 5110, Chicago, IL 60680-5110 (US). **Published** (72) Inventors; and With international search report. (75) Inventors/Applicants (for US only): GREGORY, Susan, A. Before the expiration of the time limit for amending the [US/US]; 4400 Lindell Boulevard #20A, St. Louis, MO claims and to be republished in the event of the receipt of 63108 (US). ISAKSON, Peter, C. [US/US]; 2292 Ridgley Woods Drive, Clarkson Valley, MO 63005 (US). ANDERamendments. SON, Gary [US/US]; Apartment 311, 1885 McKelvey Hill Drive, Maryland Heights, MO 63043 (US). (54) Title: COMBINATIONS, HAVING IMMUNOSUPPRESSIVE EFFECTS, CONTAINING A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE A4 HYDROLASE INHIBITOR

(57) Abstract

Treatment with a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor is described as being useful in reducing recipient rejection of transplanted organs and for treatment of autoimmune diseases.